A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Nom du journal : Invest New Drugs
Année : 2021
Volume : 39
Page de départ : 1089
Page de fin : 1098